Fresenius Medical Care stock (DE0005785802): Global dialysis leader for US investors

Fresenius Medical Care, a leading provider of dialysis products and services, maintains a strong position in the chronic kidney disease market. US investors track the company for its extensive North American operations and exposure to healthcare demand.

Fresenius Medical Care AG & Co. KGaA recently published its full-year 2025 results, showing revenue of €21.1 billion, up 3% on a reported basis and 5% at constant currency, according to company press release as of March 12, 2026. The company reported adjusted operating income of €2.2 billion, reflecting stable profitability amid rising healthcare costs. These figures underscore Fresenius Medical Care's role as the world's largest integrated provider of dialysis products and services.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Fresenius Medical Care AG & Co. KGaA
• Sector/industry: Healthcare / Dialysis products and services
• Headquarters/country: Bad Homburg, Germany
• Core markets: North America, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Dialysis services, machines, consumables
• Home exchange/listing venue: Frankfurt Stock Exchange (FME)
• Trading currency: EUR

Fresenius Medical Care: core business model

Fresenius Medical Care operates an end-to-end business model in kidney care, providing dialysis products, machines and related services to patients worldwide. The company serves approximately 345,000 patients through over 4,200 dialysis clinics as of year-end 2025, per its annual report published March 2026. Its integrated approach allows control over the full care pathway, from equipment manufacturing to clinic operations.

In North America, which accounts for over 50% of revenue, Fresenius Medical Care runs about 2,700 clinics, making it a key player for US investors exposed to the US dialysis market valued at $25 billion annually, according to annual report as of March 12, 2026. The company also produces dialyzers, hemodialysis machines and digital health solutions.

Main revenue and product drivers for Fresenius Medical Care

Dialysis services contribute around 70% of revenue, driven by recurring treatments for end-stage renal disease patients. Products like dialyzers and machines make up the balance. In 2025, North America services revenue grew 4% to €11.2 billion, supported by patient volume increases and reimbursement stability.

Key products include the 5008/6008 hemodialysis systems and NxStage home dialysis solutions, which saw 6% growth in 2025. The company's value-based care initiatives, including digital tools for patient monitoring, aim to improve outcomes and reduce costs in US Medicare programs.

Industry trends and competitive position

The global dialysis market is projected to grow at 5-6% CAGR through 2030, fueled by aging populations and rising diabetes prevalence, per sector data from IQVIA dated 2025. Fresenius Medical Care holds about 33% global market share in dialysis services and 35% in products, ahead of rivals like Baxter and Nipro.

In the US, where chronic kidney disease affects 37 million adults, Fresenius benefits from its scale and regulatory expertise. Recent expansions include new clinics in underserved areas, enhancing access for US patients.

Why Fresenius Medical Care matters for US investors

US investors value Fresenius Medical Care for its dominant position in the US dialysis sector, which represents over half its revenue. The company's ADRs trade on OTC markets, providing easy access. Exposure to US healthcare spending, projected at 20% of GDP, ties performance to Medicare reimbursement policies and private insurance trends.

Full-year 2025 financial highlights

Revenue reached €21.1 billion in 2025, with adjusted EPS of €2.05. Free cash flow before interest and tax stood at €1.4 billion. The company proposed a dividend of €1.00 per share, payable in May 2026, as announced in its March 12 results.

Conclusion

Fresenius Medical Care continues to deliver stable growth in dialysis care, with strong US market presence and solid 2025 results. Investors monitor reimbursement dynamics and innovation pipeline for future performance. The company's scale positions it well in a growing sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.